Andrew T Bender

US Patent:

20200002424, Jan 2, 2020

Filed:

Aug 15, 2019

Appl. No.:

16/541650

Inventors:

- Darmstadt, DE
Eike Staub - Darmstadt, DE
Miriam Urban - Leidersbach, DE
Sabine Raab - Rosbach, DE
Eileen Samy - Arlington MA, US
Andrew Bender - Reading MA, US
Georgianna Higginbotham - Tewksbury MA, US
Yin Wu - Andover MA, US
Daigen Xu - Westford MA, US

Assignee:

Merck Patent GmbH - Darmstadt

International Classification:

C07K 16/28
A61P 17/02
A61P 11/00
G01N 33/543

Abstract:

The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting αv-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.

US Patent:

20190144547, May 16, 2019

Filed:

Nov 22, 2016

Appl. No.:

15/778615

Inventors:

- Darmstadt, DE
Eike STAUB - Darmstadt, DE
Miriam URBAN - Leidersbach, DE
Sabine RAAB - Rosbach, DE
Eileen SAMY - Arlington MA, US
Andrew BENDER - Reading MA, US
Georgianna HIGGINBOTHAM - Tewksbury MA, US
Yin WU - Andover MA, US
Daigen XU - Westford MA, US

Assignee:

MERCK PATENT GMBH - Darmstadt

International Classification:

C07K 16/28
A61P 17/02
A61P 11/00
G01N 33/543

Abstract:

A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.